Lotze MT - Search Results

1

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.

Kang R, Hou W, Zhang Q, Chen R, Lee YJ, Bartlett DL, Lotze MT, Tang D, Zeh HJ. Kang R, et al. Among authors: lotze mt. Cell Death Dis. 2014 Oct 23;5(10):e1480. doi: 10.1038/cddis.2014.445. Cell Death Dis. 2014. PMID: 25341034 Free PMC article.

2

Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma.

Lotze MT, Zeh HJ 3rd, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R. Lotze MT, et al. J Immunother (1991). 1992 Oct;12(3):212-7. doi: 10.1097/00002371-199210000-00015. J Immunother (1991). 1992. PMID: 1359903

3

New biologic agents come to bat for cancer therapy.

Lotze MT, Rubin JT, Zeh HJ. Lotze MT, et al. Curr Opin Oncol. 1992 Dec;4(6):1116-23. Curr Opin Oncol. 1992. PMID: 1457526 Review.

4

Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.

Storkus WJ, Zeh HJ 3rd, Salter RD, Lotze MT. Storkus WJ, et al. Among authors: lotze mt. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):94-103. J Immunother Emphasis Tumor Immunol. 1993. PMID: 7506576

5

Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.

Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT. Storkus WJ, et al. Among authors: lotze mt. J Immunol. 1993 Oct 1;151(7):3719-27. J Immunol. 1993. PMID: 7690811

6

Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.

Tahara H, Zitvogel L, Storkus WJ, Zeh HJ 3rd, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT. Tahara H, et al. Among authors: lotze mt. J Immunol. 1995 Jun 15;154(12):6466-74. J Immunol. 1995. PMID: 7759882

7

Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

Tahara H, Zeh HJ 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT. Tahara H, et al. Among authors: lotze mt. Cancer Res. 1994 Jan 1;54(1):182-9. Cancer Res. 1994. PMID: 7903204

8

Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer.

Zeh HJ 3rd, Hurd S, Storkus WJ, Lotze MT. Zeh HJ 3rd, et al. Among authors: lotze mt. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):155-61. doi: 10.1097/00002371-199308000-00012. J Immunother Emphasis Tumor Immunol. 1993. PMID: 7904180

9

Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2.

Zeh HJ 3rd, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ. Zeh HJ 3rd, et al. Among authors: lotze mt. Hum Immunol. 1994 Feb;39(2):79-86. doi: 10.1016/0198-8859(94)90105-8. Hum Immunol. 1994. PMID: 8175386

10

Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis.

Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM. Evans CH, et al. Among authors: lotze mt. Hum Gene Ther. 1996 Jun 20;7(10):1261-80. doi: 10.1089/hum.1996.7.10-1261. Hum Gene Ther. 1996. PMID: 8793551 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

572 results

Search Page

Filters